About Selexis
Selexis is a company based in Plan-les-ouates (Switzerland) founded in 2001 was acquired by JSR Life Sciences in June 2017. Selexis operates in a competitive market with competitors including Harbour BioMed, Xilio Therapeutics, Zymeworks, Lassen Therapeutics and Ambrx, among others.
- Headquarter Plan-les-ouates, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
JSR Life Sciences
(Jun 14, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Selexis
Unlock access to complete
Unlock access to complete
Funding Insights of Selexis
Investors in Selexis
Selexis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include JSR Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Creates innovative technologies for raw materials in biopharmaceutical production.
|
Locked | Locked | Locked |
Investor details for Selexis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Selexis
Investment portfolio details for Selexis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Selexis
Detailed financials for Selexis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Selexis Comparisons
Peer comparison for Selexis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Selexis
Selexis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harbour BioMed, Xilio Therapeutics, Zymeworks, Lassen Therapeutics and Ambrx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody therapeutics are developed for immunology and oncology diseases.
|
|
| Locked | Locked | Locked |
Tumor-selective immunotherapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biotherapeutics targeting cancer via interleukin-11 are developed.
|
|
| Locked | Locked | Locked |
Antibody-drug conjugates are developed for cancers and metabolic disorders.
|
|
| Locked | Locked | Locked |
Antibody therapeutics for anti-cancer immune responses are developed.
|
Detailed competitors of Selexis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Selexis
Complete news archive for Selexis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Selexis
Selexis was founded in 2001 and raised its 1st funding round 14 years after it was founded.
Selexis is headquartered in Plan-les-ouates, Switzerland. It is registered at Plan-les-ouates, Geneva, Switzerland.
Selexis is developing mammalian (suspension-adapted CHO-K1) cell lines using its proprietary technology. Its SURE technology platform claims to facilitate the production of virtually any recombinant protein. It also provides drug discovery and cell line development services.
Selexis's top competitors include Xilio Therapeutics, Ambrx and Harbour BioMed.
Selexis has 1 investor. Key investors include JSR Life Sciences.